Atrys Health SA
MAD:ATRY
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/IC
Enterprise Value to Invested Capital (EV/IC) ratio compares a company`s total enterprise value to the capital invested in its business. It shows how efficiently the company`s market value reflects the funds used to generate returns.
Enterprise Value to Invested Capital (EV/IC) ratio compares a company`s total enterprise value to the capital invested in its business. It shows how efficiently the company`s market value reflects the funds used to generate returns.
Valuation Scenarios
If EV/IC returns to its 3-Year Average (0.7), the stock would be worth €3.82 (36% upside from current price).
| Scenario | EV/IC Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 0.5 | €2.82 |
0%
|
| 3-Year Average | 0.7 | €3.82 |
+36%
|
| 5-Year Average | 0.8 | €4.06 |
+44%
|
| Industry Average | 3.2 | €16.71 |
+493%
|
| Country Average | 0.9 | €4.61 |
+64%
|
Forward EV/IC
Today’s price vs future invested capital
Peer Comparison
| Market Cap | EV/IC | P/E | ||||
|---|---|---|---|---|---|---|
| ES |
A
|
Atrys Health SA
MAD:ATRY
|
214.1m EUR | 0.5 | -2.1 | |
| US |
|
CVS Health Corp
NYSE:CVS
|
104.3B USD | 0.8 | 59 | |
| US |
C
|
Cigna Group
XMUN:CGN
|
72.9B EUR | 0.8 | 14.1 | |
| US |
|
Cigna Corp
NYSE:CI
|
74.5B USD | 0 | 12.5 | |
| DE |
|
Fresenius SE & Co KGaA
XETRA:FRE
|
23.2B EUR | 0.8 | 18.4 | |
| DE |
|
Fresenius Medical Care AG
XMUN:FME
|
22.4B EUR | 1 | 22.8 | |
| US |
|
Quest Diagnostics Inc
NYSE:DGX
|
21.4B USD | 1.8 | 21 | |
| US |
|
Laboratory Corporation of America Holdings
NYSE:LH
|
21B USD | 1.5 | 24 | |
| DE |
F
|
Fresenius Medical Care AG & Co KGaA
XETRA:FME
|
10.8B EUR | 0.6 | 11 | |
| US |
|
Guardant Health Inc
NASDAQ:GH
|
11.4B USD | 15.8 | -27.5 | |
| US |
|
DaVita Inc
NYSE:DVA
|
10.4B USD | 1.2 | 13.9 |
Market Distribution
| Min | 0 |
| 30th Percentile | 0.7 |
| Median | 0.9 |
| 70th Percentile | 1.3 |
| Max | 31.5 |
Other Multiples
Atrys Health SA
Glance View
Atrys Health SA is a biomedical company, which engages in the research and development of diagnostic services. The company is headquartered in Madrid, Madrid and currently employs 2,397 full-time employees. The company went IPO on 2016-07-22. The company operates under Atrys brand name. Atrys is a clinical and translational research laboratory dedicated to the diagnosis, prognosis and treatment of cancer, including hematologic and solid malignancies. The company has four areas of activity: Laboratory, Telemedicine, Radiotherapy, as well as Research and Development (R&D). The firm has its diagnostic laboratories and translational research in Barcelona and Granada, and offices in Madrid, Spain.
